Structural bioinformatics study of cyclin-dependent kinases complexed with inhibitors

Ecletica Quimica

Volumn 28, Issue 1, 2003, Pages 45-53

  Canduri, F ^a   Da Silveira, N J F ^a   Camera Jr , J C ^a   De Azevedo Jr , W F ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

Bioinformatics; CDK; Drug design; Flavopiridol; Structure

Indexed keywords

2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 6 N (3,3 DIMETHYLALLYL)ADENINE; 6 O CYCLOHEXYLMETHYLGUANINE; ADENINE DERIVATIVE; ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; DESCHLOROFLAVOPIRIDOL; FLAVONE DERIVATIVE; FLAVOPIRIDOL; HYMENIALDESINE; INDIRUBIN; NU 3027; OLOMOUCINE; PURVALANOL B; ROSCOVITINE; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; COMPLEX FORMATION; CORRELATION ANALYSIS; DRUG BINDING; DRUG MECHANISM; MOLECULAR MODEL;

EID: 0344599384     PISSN: 01004670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-46702003000100006     Document Type: Article

References (41)

1. ALVAREZ, A.; TORO, R.; CÁCERES, A.; MACCIONI, R. B. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett, v. 459, n. 3, p. 421-426, 1999.
2. ARRIS, C. E.; BOYLE, F. T.; CALVERT, A. H.; CURTIN, N. J.; ENDICOTT, J. A.; GARMAN, E. F.; GIBSON, A. E.; GOLDING, B. T.; GRANT, S.; GRIFFIN, R. J.; JEWSBURY, P.; JOHNSON, L. N.; LAWRIE, A. M.; NEWELL, D. R.; NOBLE, M. E.; SAUSVILLE, E. A.; SCHULTZ, R.; YU, W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem., v. 43, n. 15, p. 2797-2804, 2000.
3. BLUNDELL, T. L.; CARNEY, D.; GARDNER, S.; HAYES, F.; HOWLIN, B.; HUBBARD, T.; OVERINGTON, J.; SINGH, D. A.; SIBANDA, B. L.; SUTCLIFFE, M. 18th Krebs, Hans lecture - knowledge-based protein modeling and design. Eur. J. Biochem., v. 172, n. 3, p. 513-520, 1988.
4. BLUNDELL, T. L.; SIBANDA, B. L.; STERNBERG, M. J.; THORNTON, J. M. Knowledge-based prediction of protein structures and the design of novel molecules. Nature, v. 326, n. 6111, p. 347-352, 1987.
5. BRAUN, W.; GO, N. Calculation of protein conformations by proton-proton distance constraints. A new efficient algorithm. J. Mol. Biol., v. 186, n. 3, p. 611-626, 1985.
6. BROOKS, B. R.; BRUCCOLERI, R. E.; OLAFSON, B. D.; STATES, D. J.; SWAMINATHAN, S.; KARPLUS, M. CHARMM: a program for macromolecular energy minimization and dynamics calculations. J. Comp. Chem., v. 4, p. 187-217, 1983.
7. CANDURI, F.; TEODORO, L. G. V. L.; LORENZI, C. C. B.; HIAL, V.; GOMES, R. A. S.; RUGGIERO NETO, J.; DE AZEVEDO, W. F. JR. Crystal structure of human uropepsin at 2.45Å resolution. Acta Crystallogr., v. D57, p. 1560-1570, 2001.
8. CARLSON, B.A.; LAHUSEN, T.; SINGH, S.; LOAIZA-PEREZ, A.; WORLAND, P. J.; PESTELL, R.; ALBANESE, C.; SAUSVILLE, E. A.; SENDEROWICZ, A. M. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., v. 59, p. 4634-4641, 1999.
9. CHAO, S. H.; FUJINAGA, K.; MARION, J. E.; TAUBE, R.; SAUSVILLE, E. A.; SENDEROWICZ, A. M.; PETERLIN, B. M; PRICE, D. H. J. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem., v. 275, n. 37, p. 28345-28348, 2000.
10. CLARE, P. M.; POORMAN, R. A.; KELLEY, L. C.; WATENPAUGH, K. D.; BANNOW, C. A.; LEACH, K. L. The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism. J. Biol. Chem., v. 276, p. 48292-48299, 2001.
11. COLLABORATIVE computational project n. 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., v. D50, p. 760-763, 1994.
12. CORPET, F. Multiple sequence alignment with hierarchical clustering. Nucl. Acids Res., v. 16, n. 22, p.10881-10890, 1988.
13. DE AZEVEDO, W. F. JR.; CANDURI, F.; FADEL, V.; TEODORO, L. G. V. L.; HIAL, V.; GOMES, R. A. S. Molecular model for the binary complex of uropepsin and pepstalin. Biochem. Biophys. Res. Commun., v. 287, n. 1, p. 277-281, 2001.
14. DE AZEVEDO, W. F. JR.; CANDURI, F.; SILVEIRA, N. J. F. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys. Res. Commun., v. 293, p. 566-571, 2002.
15. DE AZEVEDO, W. F. JR.; GASPAR, R. T.; CANDURI, F.; CAMERA, J. C. JR.; SILVEIRA, N. J. F. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. Biochem. Biophys. Res. Commun., v. 297, p. 1154-1158, 2002.
16. DE AZEVEDO, W. F. JR.; LECLERC, S.; MEIJER, L.; HAVLICEK, L.; STRNAD, M.; KIM, S.-H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human CDK2 complexed with roscovitine. Eur. J. Biochem., v. 243, p. 518-526, 1997.
17. DE AZEVEDO, W. F. JR.; MUELLER-DIECKMANN, H.;J.; SCHULZE-GAHMEN, U.; WORLAND, P. J.; SAUSVILLE, E.; KIM S.-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA., v. 93, n. 7, p. 2735-2740, 1996.
18. DEBONDT, H. L.; ROSENBLATT, J.; JANCARIK, J.; JONES, H. D.; MORGAN, D. O.; KIM, S.-H. Crystal structural of cyclin-dependent kinase 2. Nature, v. 363, p. 595-602, 1993.
19. DESAI, D.; GU, Y.; MORGAN, D. O. Activation of human cyclin-dependent kinases in vitro. Mol. Biol. Cell, v. 3, p. 571-582, 1992.
20. GRAY, N.; DETIVAUD, L.; DOERIG, C.; MEIJER, L. ATP-site directed inhibitors of cyclin-dependent kinases.
21. GRAY, N. S.; WODICKA, L.; THUNNIESSEN, A. M.; NORMAN, T. C.; KWON, S.; ESPINOZA, F. H.; MORGAN, D. O.; BARNES, G.; LECLERC, S.; MEIJER, L.; KIM, S. H.; LOCKHART, D. J.; SCHULTZ, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science, v. 281, p. 533-538, 1998.
22. HOESSEL, R.; LECLERC, S.; ENDICOTT, J. A.; NOBEL, M. E.; LAWRIE, A.; TUNNAH, P.; LEOST, M.; DAMIENS, E.; MARIE, D.; MARKO, D.; NIEDERBERGER, E.; TANG, W.; EISENBRAND, G.; MEIJER, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol., v. 1, n. 1, p. 60-67, 1999.
23. KIM, S.-H.; SCHULZE-GAHMEN, U.; BRANDSEN, J.; DE AZEVEDO, W. F. JR. Structural basis for chemical inhibitor of CDK2. Prog. Cell Cycle Res., v. 2, p. 137-145, 1996.
24. KRAULIS, P. MOLSCRIPT: a program to produce both detailed and schematic plots of proteins. J. App. Cryst., v. 24, p. 946-950, 1991.
25. KROEMER, R. T.; DOUGHTY, S. W.; ROBINSON, A. J.; RICHARDS, W. G. Prediction of the three-dimensional structure of human interleukin-7 by homology modeling. Protein Eng., v. 9, n. 6, p. 493-498, 1996.
26. LASKOWSKI, R. A.; MACARTHUR, M. W.; SMITH, D. K.; JONES, D. T.; HUTCHINSON, E. G.; MORRIS, A, L.; NAYLOR, D.; MOSS, D. S.; THORTON, J. M. PROCHECK v.3.0: program to check the stereochemistry quality of protein structures - operating instructions, [s.l.:s.n.], 1994.
27. LAWRIE, A. M.; NOBLE, M. E.; TUNNAH, P.; BROWN, N. R.; JOHNSON, L. N.; ENDICOTT, J. A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol., v. 4, p. 796, 1997.
28. MEIJER, L.; BORGNE, A.; MULNER, O.; CHONG, J. P.; BLOW, J. J.; INAGAKI, N. Biochemical and cellular effects of roscovitine, a patent and selective inhibitor of the cyclin-dependent kinases CDK2 and CDK5. Eur. J. Biochem., v. 243, p. 527-536, 1997.
29. MEIJER, L.; THUNNISSEN, A. M.; WHITE, A. W.; GARNIER, M.; NIKOLIC, M.; TSAI, L. H.; WALTER, J.; CLEVERLEY, K. E.; SALINAS, P. C.; WU, Y. Z.; BIERNAT, J.; MANDELKOW, E. M.; KIM, S.-H.; PETTIT, G. R. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol., v. 7, n. 1, p. 51-63, 2000.
30. NICHOLLS, A.; SHARP, K. A.; HONIG, B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins, v. 11, n. 4, p. 281-296, 1991.
31. NORBURY, C.; NURSE, P. Animal cell cycles and their control. Annu. Rev. Biochem., v. 61, p. 441-470, 1992.
32. OIKONOMAKOS, N. G.; SCHNIER, J. B.; ZOGRAPHOS, S. E.; SKAMNAKI, V. T.; TSITSANOU, K. E.; JOHNSON, L. N. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem., v. 275, n. 44, p. 34566-34573, 2000.
33. PATRICK, G. N.; ZUKERBERG, L.; NIKOLIC, M.; DE LA MONTE, S.; DIKKES, P.; TSAI, L. H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature, v. 402, n. 6762, p. 615-22, 1999.
34. RICHARDSON, H. E.; STUELAND, C. S.; THOMAS, J.; RUSSEL, P.; REED, S. I. Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe. Genes Dev., v. 4, p. 1332-1344, 1990.
35. SALI, A. Modeling mutations and homologous proteins. Curr. Opin. Biotechnol., v. 6, n. 4, p. 437-451, 1995.
36. SALI, A.; BLUNDELL, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol., v. 234, p. 779-815, 1993.
37. SALI, A.; OVERINGTON, J. P. Derivation of rules for comparative protein modeling from a database of protein structure alignments. Protein Sci., v. 3, n. 9, p. 1582-1596, 1994.
38. SALI, A.; POTTERTON, L.; YUAN, F.; VAN VLIJMEN, H.; KARPLUS, M. Evaluation of comparative protein modeling by MODELLER. Proteins, v. 23, n. 3, p. 318-326, 1995.
39. SCHULTZE-GAHMEN, U.; BRANDSEN, J.; JONES, H. D.; MORGAN, D. O.; MEIJER, I.; VESELY, J. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in the complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins, v. 22, p. 378-391, 1995.
40. SENDEROWICZ, A. M.; SAUSVILLE, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst., v. 92, n. 5, p. 376-387, 2000.
41. SEROTA, S.; RADSIO-ANDZELM, E. Three protein kinase structures define a common motif. Structure, v. 2, p. 345-355, 1994.